Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Total Current Liabilities (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Total Current Liabilities for 5 consecutive years, with $39.1 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 67.0% to $39.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $39.1 million through Dec 2025, up 67.0% year-over-year, with the annual reading at $39.1 million for FY2025, 67.0% up from the prior year.
  • Total Current Liabilities hit $39.1 million in Q4 2025 for ARS Pharmaceuticals, down from $50.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $50.9 million in Q3 2025 to a low of $2.4 million in Q4 2023.
  • Historically, Total Current Liabilities has averaged $16.7 million across 5 years, with a median of $11.4 million in 2021.
  • Biggest five-year swings in Total Current Liabilities: tumbled 74.0% in 2022 and later skyrocketed 880.34% in 2024.
  • Year by year, Total Current Liabilities stood at $8.2 million in 2021, then tumbled by 33.5% to $5.4 million in 2022, then tumbled by 56.08% to $2.4 million in 2023, then surged by 880.34% to $23.4 million in 2024, then soared by 67.0% to $39.1 million in 2025.
  • Business Quant data shows Total Current Liabilities for SPRY at $39.1 million in Q4 2025, $50.9 million in Q3 2025, and $45.6 million in Q2 2025.